StockpollyBeta
Get App
Popularity #2,912
AVXL · NASDAQ · Biotechnology

Anavex Life Sciences (AVXL)

Develops oral investigational therapies for neurodegenerative and neurodevelopmental diseases.

$2.33
vs last close−0.14 (−5.47%)

In millions of USD, except per-share figures

In millionsQ4 FY23Sep 2023Q1 FY24Dec 2023Q2 FY24Mar 2024Q3 FY24Jun 2024Q4 FY24Sep 2024Q1 FY25Dec 2024Q2 FY25Mar 2025Q3 FY25Jun 2025Q4 FY25Sep 2025Q1 FY26Dec 2025Q2 FY26Mar 2026Q3 FY26Jun 2026
131113151414131411767
Research & development1091012121010107544
333333354222
General & administrative333333354202
Operating income−13−11−13−15−14−14−13−14−11−7−6−7
232231111113
Interest income222221111110
Other non-operating income−2−30−1−3000−4−10−3
Income before tax−10−9−11−12−12−12−11−13−10−6−5−3
Income tax expense000000000000
Net income from continuing operations−10−9−11−12−12−12−11−13−10−6−5−3
Net income−10−9−11−12−12−12−11−13−10−6−5−3
EPS, basic−$0.13−$0.10−$0.13−$0.14−$0.14−$0.14−$0.13−$0.16−$0.11−$0.06−$0.06−$0.03
EPS, diluted−$0.13−$0.10−$0.13−$0.14−$0.14−$0.14−$0.13−$0.16−$0.11−$0.06−$0.06−$0.03
Weighted average shares, basic808282858485858586899391
Weighted average shares, diluted808282858485858586899391
EBITDA−10−9−12−14−12−14−12−14−6−6−6−3
EBIT−10−9−12−14−12−14−12−14−6−6−6−3